PVLA (Palvella Therapeutics) Total Stockholders Equity: $216.87 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PVLA Palvella Therapeutics Inc PVLA
14 GF Score
Price $142.04
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Total Stockholders Equity?

Palvella Therapeutics PVLA -0.38% 14 Total Stockholders Equity is $216.87 Mil as of Jun. 2026. GuruFocus rates PVLA with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Palvella Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $216.87 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Palvella Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $15.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Palvella Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Palvella Therapeutics  (NAS:PVLA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Palvella Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(216.867-0)/14.396
=15.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Palvella Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.217 + 0.318) / 216.867
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Total Stockholders Equity Related Terms

Palvella Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Total Stockholders Equity Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
-23.17 -3.88 62.61 27.98

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.78 38.68 27.98 232.31 216.87
PVLA
14GF Score
Palvella Therapeutics Inc PVLA
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $216.87 Mil mean?
Palvella Therapeutics (PVLA) has a Total Stockholders Equity of $216.87 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Total Stockholders Equity too high?
Palvella Therapeutics' current Total Stockholders Equity is $216.87 Mil. Overall, Palvella Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Total Stockholders Equity compare to AUPH and URGN?
Palvella Therapeutics' Total Stockholders Equity of $216.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Palvella Therapeutics and its competitors. Palvella Therapeutics's current Total Stockholders Equity is $216.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (PVLA) has a current Total Stockholders Equity of $216.87 Mil. The current Total Stockholders Equity is $216.87 Mil. Palvella Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Palvella Therapeutics (PVLA), the current Total Stockholders Equity is $216.87 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PI6:Germany
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
14GF Score

Get the complete analysis for PVLA

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$142.04
Price